Last reviewed · How we verify
Inactivated Polio Vaccine
At a glance
| Generic name | Inactivated Polio Vaccine |
|---|---|
| Also known as | Imovax Polio, Imovax, Sanofi Pasteur SA |
| Sponsor | China National Biotec Group Company Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated Polio Vaccine CI brief — competitive landscape report
- Inactivated Polio Vaccine updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI